VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2015 | Ibrutinib vs temsirolimus in relapsed/refractory mantle cell lymphoma

Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of the RAY (MCL3001) study of ibrutinib vs temsirolimus in relapsed/refractory mantle cell lymphoma, presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. The primary endpoint was progression-free survival (PFS), which was 14.8 months for the ibrutinib arm and 6.6 months for the temsirolimus arm.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter